TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed advanced or metastatic adenocarcinoma of the colon and rectum Surgically unresectable disease Measurable disease Disease outside the prior radiotherapy port and/or progressive disease within the previously irradiated volume~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 No hemorrhagic events within the past 6 months Hepatic: Bilirubin normal SGOT normal INR no greater than 1.5 Renal: Creatinine no greater than 1.5 times upper limit of normal Cardiovascular: No thromboembolic events within the past 6 months Pulmonary: No evidence of pneumonia Other: No known hypersensitivity to recombinant humanized murine monoclonal antibodies No evidence of significant active infection (e.g., peritonitis or wound abscess) Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent sargramostim (GM-CSF) Chemotherapy: At least 12 months since prior fluorouracil-based adjuvant chemotherapy No prior adjuvant irinotecan Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics At least 2 weeks since prior radiotherapy and recovered Surgery: See Disease Characteristics Other: No prior therapy for advanced disease No concurrent therapeutic anticoagulation except for low-dose coumadin for maintenance of indwelling catheters

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a Major Depressive Episode (MDE), is diagnosed with Major Depressive Disorder (MDD) according to DSM-5® and would benefit from pharmacological treatment with vortioxetine. The current MDE should be confirmed using the Mini International Neuropsychiatric Interview (MINI).~* The patient has a CGI-S ≥4 at screening.~Exclusion Criteria:~* The patient has a significant risk of suicide according to investigator's clinical judgment or has made an actual suicide attempt in the period of 6 months prior to screening.~* The patient previously received vortioxetine.~Other in- and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine (Type: EXPERIMENTAL): flexible-dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. hepatic cirrhosis patients after 7days treatment of loop diuretics and aldosterone antagonist but still with ascites~2. Hospitalized patients or those who can be hospitalized in this trial between observation period and posttherapeutic observation (Visits at clinic will be allowed after day 8);~3. During the observation period (-3 day to -1 day ), subjects whose body weight difference fall within ±1.0 kg range 2 days (day-2 and day -1) prior to initiation of trial drug treatment;~4. Ages: ≥18 and ≤75 years of age;~5. Genders: men or women;~6. Signed the Informed Consent Form.~Exclusion Criteria:~1. Patients with the following diseases, complications or symptoms:~   * Hepatic encephalopathy (Coma scale Note 1) grade 2 or higher);~  * Malignant ascites;~  * Uncontrolled spontaneous bacterial peritonitis;~  * Patients are likely to experience alimentary tract hemorrhage during the trial;~  * Heart failure (NYHA cardiac function scale Note 2) stages 3 and 4);~  * Anuria (daily urine volume below 100mL);~  * Dysuria resulting from urethral stricture, calculus and tumors.~2. Patients with the following medical history:~   * Alimentary tract hemorrhage within 10 days prior to screening;~  * Cerebrovascular accident within 1 month prior to screening;~  * Gout attack within 1 month prior to screening;~  * Past allergy or hypersensitive reactions to benzodiazepines (e.g. benazepril hydrochloride)~3. Systolic pressure below 90mmHg at screening;~4. Patients with the following abnormalities in laboratory examinations at screening:~   Serum creatinine exceeds 2.5X upper limits of normal, serum Na+\>145mmol/L (or exceeds upper limits of normal), serum K+\>5.5mmol/L, uric acid\>8.0mg/dL (476μmol/L), Child-pugh scale greater than 12.~5. Patients cannot take drugs orally;~6. Pregnant or breast-feeding patients or women at child-bearing ages without taking acceptable contraceptive measures;~7. Patients received albumin or other blood preparations within 4 days prior to trial drug administration;~8. Patients participated in clinical trials of other drugs within 1 month prior to screening;~9. Patients participated in tolvaptan trials and took tolvaptan previously;~10. Patients are unsuitable to participate in this trial in investigators' opinion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1. tolvaptan (Type: EXPERIMENTAL): 15 mg, P.O., Qd, for 7 days,
- 2 tolvaptan (Type: EXPERIMENTAL): 30 mg, P.O., Qd, for 7 days,
- 3. Placebo (Type: EXPERIMENTAL): 30mg,P.O.,Qd, for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Dehydroepiandrosterone Supplementation on Cumulus Cells Gene Expression Under Controlled Ovarian Hyper-stimulation in Patients With Diminished Ovarian Reserve

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* DOR: antral follicle count (AFC) less than 5, AntiMullerian hormone (AMH) less than 1.0 ng/ml, and previous total retrieved oocyte less than 5.~* Normal Control: antral follicle count (AFC) equal to or more than 5, AntiMullerian hormone (AMH) equal to or more than 1.0 ng/ml, and previous total retrieved oocyte equal to or more than 5.~Patient provided signed informed consent.~Exclusion Criteria:~* Patient who has the allergic history or contraindication to DHEAS usage.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- DHEAS in DOR Group (Type: ACTIVE_COMPARATOR): Additional usage of DHEAS supplement in patients with DOR under ovarian hyper-stimulation protocol.
- Normal Control (Type: ACTIVE_COMPARATOR): Patients under ovarian hyper-stimulation protocol. No DHEAS supplement.
- Shame DOR Group (Type: ACTIVE_COMPARATOR): Patients with DOR under ovarian hyper-stimulation protocol. No DHEAS supplement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapy for Pediatric Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible patients must have histologically confirmed previously untreated Hodgkin's disease (Patients receiving limited emergent RT or steroid therapy because of cardiopulmonary decompensation or spinal cord compression will be eligible for protocol enrollment).~* Patients must be 21 years of age or younger~* Ann Arbor stages IIB-IV~* No prior treatment.~* No pregnant or lactating women.~* Signed informed consent~* If re-evaluation of a patient's disease shows favorable risk features or intermediate risk features, the patient will be removed from the HOD99 study and consented to the respective HOD08 or HOD05 study.~Inclusion: treatment of favorable risk features:~* Ann Arbor IA or IIA with:~  1. Non-bulky mediastinal disease (\<33% mediastinal to thoracic ratio on chest x ray)~ 2. Ann Arbor stage IA or IIA with any of the following features: (1) E lesions (s), (2) 3 or more nodal sites involved, (3) Bulky mediastinal adenopathy (mediastinal mass to thoracic cavity ratio 33% or greater by chest radiograph)~     Inclusion: unfavorable risk features:~* Stage must be classified as one of the following:~  1. Ann Arbor stage IIB, IIIB, or any IV

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Unfavorable Risk, Group 2 (Type: EXPERIMENTAL): Unfavorable risk, group 2 arm in patients with Hodgkin's disease (n=146)
- Favorable Risk (Type: EXPERIMENTAL): Favorable Risk arm in patients with Hodgkin's Disease (n=91).
- Intermediate Risk (Type: EXPERIMENTAL): Intermediate Arm in patients with Hodgkins's disease (n=46).
- Unfavorable Risk, Group 1 (Type: EXPERIMENTAL): Unfavorable risk group 1 closed early due to excessive number of adverse events (n=13).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy postmenopausal women~Exclusion Criteria:~* Previous treatment with other osteoporosis medication~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive H. pylori-infected participants, at least 18 years of age, with endoscopically proven peptic ulcer diseases or gastritis who failed first-line eradication therapies with standard triple regimens (PPI twice daily, 500 mg of clarithromycin twice daily and 1 g of amoxicillin twice daily)~Exclusion Criteria:~* Ingestion of antibiotics, bismuth, or proton-pump inhibitors within the prior 4 weeks~* Use of non-steroidal anti-inflammatory drugs within the prior 4 weeks~* Participants with allergic history to the medications used~* Participants with previous gastric surgery~* The coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)~* Pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sequential therapy (Type: EXPERIMENTAL): Esomeprazole (Nexium)(40 mg) 1 tablet twice daily, amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 5 days followed by esomeprazole (Nexium) (40 mg) twice daily, levofloxacin(Cravit)(500 mg), 1 tablet once daily and metronidazole (Flagyl)(250 mg) 2 tablets three times daily for 5 days
- Triple therapy (Type: ACTIVE_COMPARATOR): Esomeprazole (Nexium)(40 mg) 1 tablet twice daily; amoxicillin (Amolin)(500 mg) 2 tablets twice daily and levofloxacin(Cravit)(500 mg), 1 tablet once daily for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~patients with positive oral/nasal swabs~Exclusion Criteria:~Children under 5 years old Pregnant women Previous reports of allergy to any of the drugs used in the clinical trial

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mild cases (Type: None): This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting only mild symptoms such as: fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain.
- Moderate cases (Type: None): This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 3 severe symptoms (i.e. fever above 38.5 °C, diarrhea with more than 3 daily depositions, flictenular conjunctivitis, strong desaturation (92% or less), tachypnea (FR\> 25 / minute) or 2 severe symptoms + 2 mild symptoms (fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain)
- Severe cases (Type: None): This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 4 severe symptoms or 3 severe symptoms and not less than 2 mild symptoms or clinical signs of bilateral viral pneumonia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mucinex Exploratory Cold Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* common cold symptoms~* meet symptom severity~* females of child-bearing potential must have negative pregnancy test and use effective birth control~Exclusion Criteria:~* chronic respiratory conditions~* significant heart, kidney, liver, or lung disease, uncontrolled hypertension or diabetes, cystic fibrosis, thyroid disorder~* pregnant or lactating~* known malignancy~* participation in any other clinical trial within 30 days of baseline~* related to another enrolled patient or persons involved directly or indirectly with the conduct of this study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mucinex (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~Distal subungual onychomycosis of the great toenail, affecting at least ≥25 to ≤75% of nail.~Positive culture for dermatophytes and positive KOH.~Nail ≤ 3 mm thick at the distal end.~At least ≥ 2 mm of the proximal end of the great toenail must be free of infection.~Subjects must be able to swallow tablets.~Women of childbearing potential and males must use acceptable birth control methods throughout the study.~Key Exclusion Criteria:~Presence of subungual hematoma or melanonychia.~Presence of dermatophytoma/nail streaks and severe onychorrhexis.~Significant dystrophy or anatomic abnormalities of the great toenail.~Presence of any other infections of the foot.~Evidence of clinically significant major organ disease.~Poorly controlled diabetes mellitus.~Onychomycosis involving more than 8 toe nails.~Recent use of systemic antifungal therapy.~Recent of any topical antifungal nail therapy.~Recent use of systemic corticosteroid therapy.~Recent use of immunosuppressive medication.~History of prolonged QT intervals.~Known human immunodeficiency virus (HIV) infection.~Known significant renal or hepatic impairment.~Known history of intolerance or hypersensitivity to azole antifungal drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Low dose 12-week (Type: EXPERIMENTAL): 2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
- Low dose 24-week (Type: EXPERIMENTAL): 2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
- High dose 12-week (Type: EXPERIMENTAL): 4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
- High dose 24-week (Type: EXPERIMENTAL): 4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 22 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 4 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Selinexor in Advanced Liposarcoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ≥12 years of age~2. Body surface area (BSA) ≥ 1.2 m2~3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of DDLS requiring treatment~4. Must have measurable disease per RECIST v1.1 Response Criteria~5. Radiologic evidence of disease progression within 6 months prior to randomization. If the patient received other intervening therapy after documented disease progression, further disease progression must be documented after the completion of the intervening therapy~6. Must have had at least 2 prior lines of systemic therapy for liposarcoma (not to exceed 5 prior lines)~7. If patient received any previous systemic therapy, the last dose must have been ≥ 21 days prior to randomization (or ≥ 5 half-lives of that drug, whichever is shorter) with all clinically significant therapy-related toxicities having resolved to ≤ Grade 1~Exclusion Criteria:~1. Patients with pure well-differentiated liposarcoma (WDLS), myxoid/round cell or pleomorphic tumor histologic subtypes~2. Known active hepatitis B (HepB), hepatitis C (HepC) or human immunodeficiency virus (HIV) infection~3. Known central nervous system metastases

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 2 Double-blinded: Selinexor (Type: EXPERIMENTAL): Participants received a fixed blinding dose of 60 milligrams (mg) selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until progressive disease (PD).
- Phase 3 Double-blinded: Selinexor (Type: EXPERIMENTAL): Participants received a fixed blinding dose of 60 mg selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD.
- Phase 2 Double-blinded: Placebo Followed by Open Label- Selinexor (Type: PLACEBO_COMPARATOR): Participants received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD in double-blinded treatment period. Participants in the placebo group who had PD during the Phase 2 double-blinded treatment, will be elected to cross over to open-label selinexor.
- Phase 3 Double-blinded: Placebo Followed by Open Label- Selinexor (Type: PLACEBO_COMPARATOR): Participants received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD or development of unacceptable toxicity. Participants in the placebo group who had PD during the Phase 3 double-blinded treatment, will be elected to cross over to open-label selinexor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacotoxicology of Trichloroethylene Metabolites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~Exclusion Criteria:~* Pregnancy~* Other medications~* Psychiatric illness on meds~* Abnormal labs

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- No EGT Allele, slow metabolizers for DCA (Type: EXPERIMENTAL): Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
- 1+ EGT Allele, fast metabolizers for DCA (Type: EXPERIMENTAL): Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete